Background-The relations of lipid concentrations to heart failure (HF) risk have not been elucidated comprehensively. Methods and Results-In 6860 Framingham Heart Study participants (mean age, 44 years; 54% women) free of baseline coronary heart disease, we related high-density lipoprotein cholesterol (HDL-C) and non-HDL-C to HF incidence during long-term follow-up, adjusting for clinical covariates and myocardial infarction at baseline and updating these at follow-up examinations. We evaluated dyslipidemia-specific population burden of HF by calculating population attributable risks. During follow-up (mean of 26 years), 680 participants (49% women) developed HF. Unadjusted HF incidence in the low (Ͻ160 mg/dL) versus high (Ն190 mg/dL) non-HDL-C groups was 7.9% and 13.8%, respectively, whereas incidence in the high (Ն55 [men], Ն65 [women] mg/dL) versus low (Ͻ40 [men], Ͻ50 [women] mg/dL) HDL-C groups was 6.1% and 12.8%, respectively. In multivariable models, baseline non-HDL-C and HDL-C, modeled as continuous measures, carried HF hazards (confidence intervals) of 1.19 (1.11 to 1.27) and 0.82 (0.75 to 0.90), respectively, per SD increment. In models updating lipid concentrations every 8 years, the corresponding hazards (confidence intervals) were 1.23 (1.16 to 1.31) and 0.77 (0.70 to 0.85). Participants with high baseline non-HDL-C and those with low HDL-C experienced a 29% and 40% higher HF risk, respectively, compared with those in the desirable categories; the population attributable risks for high non-HDL-C and low HDL-C were 7.5% and 15%, respectively. Hazards associated with non-HDL-C and HDL-C remained statistically significant after additional adjustment for interim myocardial infarction. Conclusions-Dyslipidemia carries HF risk independent of its association with myocardial infarction, suggesting that lipid modification may be a means for reducing HF risk. (Circulation. 2009;120:2345-2351.)
H eart failure (HF) is a syndrome associated with high morbidity and mortality and enormous economic burden, rendering prevention a priority. 1 Elucidating modifiable risk factors for HF will aid the identification and promulgation of prevention strategies. Dyslipidemia is a wellestablished risk factor for coronary heart disease (CHD), 2 and results from clinical trials of lipid-modifying therapy demonstrate that treatment with statins also decreases the incidence of HF. 3 This finding suggests that dyslipidemia is a risk factor for HF, although the association may be mediated by the occurrence of myocardial infarction (MI).
Clinical Perspective on p 2351
Although previous studies assessed the associations between individual lipid measures and HF, 4, 5 the role of lipids in the incidence of HF in people without preexisting CHD has not been investigated systematically in a community-based setting in a prospective fashion, with appropriate adjustment for clinical factors (including interim occurrence of MI) that influence HF risk. Elevated low-density lipoprotein cholesterol and decreased high-density lipoprotein cholesterol (HDL-C) have been shown to be associated with reduced systolic and diastolic left ventricular function. 6, 7 In addition, a previous investigation from the Framingham Heart Study detected a direct association between the ratio of total cholesterol to HDL-C and HF risk, 5 suggesting that either elevated total cholesterol or lowered HDL-C may influence HF risk. We therefore hypothesized that increasing levels of non-HDL-C and decreasing levels of HDL-C are associated with increased risk for HF. We further theorized that the associations between lipid concentrations and HF will persist even after adjustment for occurrence of interim MI.
Methods

Study Sample and Design
The design and characteristics of the Framingham Heart Study original cohort 8, 9 and offspring cohort 10 have been detailed elsewhere. Briefly, the original cohort included 5209 participants who were enrolled in 1948 and have been evaluated every 2 years. The offspring cohort, consisting of 5124 individuals who are children (or spouses of children) of the original cohort, was enrolled in 1971 and has been examined approximately every 4 years.
Attendees of examinations 11 (1968 -1971) and 12 (1971-1974 ) of the original cohort and examination 1 (1971-1974) of the offspring cohort who had lipids measured formed the baseline for this analysis (nϭ7598). We excluded 510 participants because of prevalent HF, MI, angina pectoris, coronary insufficiency, valve disease, or use of lipid therapy at the baseline examination and 228 participants because of missing covariate information. Valve disease was defined as a systolic murmur grade 3 of 6 or louder or any diastolic murmur, as auscultated by a physician during the clinical examination. A total of 6860 participants (mean age, 44 years; 54% women) were eligible for this investigation. All participants provided written informed consent. The study was approved by the institutional review board of Boston University Medical Center.
Measurement of Circulating Lipids
Plasma samples for lipid measurement were collected in 0.1% EDTA, and lipid concentrations were measured on freshly drawn plasma before freezing. Total cholesterol was measured by the Abell and Kendall method up to original cohort examination 20 (1986 -1990 ) and subsequently by standard enzymatic methods. 11, 12 HDL-C was measured after heparin-manganese chloride precipitation 13 (up to offspring cohort examination cycle 4; years 1987-1991) and subsequently by dextran sulfate-manganese precipitation. HDL-C was subtracted from total cholesterol to obtain non-HDL-C. The utility of non-HDL-C as a predictor of the lipoprotein-related risk for atherosclerotic disease has been established previously. 14
Determination of HF Events
An ongoing review of clinic charts, hospitalization and physician records, and mailed health history updates from participants is performed at the Framingham Heart Study, according to prespecified protocols. All suspected cardiovascular events were reviewed by a committee of 3 physicians according to established criteria. 15 For this investigation, the outcome of interest was the first occurrence of HF as adjudicated by an end points committee. The criteria for HF have been published previously 16 and are detailed in Table I in the online-only Data Supplement.
Definitions of Covariates
Body mass index was calculated as weight in kilograms divided by height in meters squared. At each examination, blood pressure was measured twice by a physician on the left arm in the seated position using a mercury column sphygmomanometer, and we used the average of these values. Current smoking was defined as smoking (on average) 1 or more cigarettes per day in the year preceding an examination. Diabetes mellitus was defined as fasting plasma glucose of Ն126 mg/dL, a nonfasting glucose of Ն200 mg/dL, or current use of insulin or oral hypoglycemic therapy. Treatment status for hypertension was defined as receiving blood pressure-lowering medications for treatment of hypertension. Interim MI was defined as MI occurring between the examination at which lipids were measured and the date of diagnosis of HF.
Statistical Analysis
We related baseline HDL-C and non-HDL-C, as both continuous and categorical variables (see below), to HF incidence. We used Cox proportional hazards models (after confirming that the assumption of proportionality was met) to relate lipid concentrations (continuous and categorical) to the incidence of HF in stepwise fashion. We constructed 2 models: a model adjusting for traditional HF risk factors (age, sex, systolic blood pressure, hypertension treatment, body mass index, smoking status, and diabetes mellitus) and a model adjusting for traditional covariates plus interim MI as a time-dependent covariate (participants with MI at baseline were excluded from eligibility). Furthermore, we examined lipid categories published by the National Cholesterol Education Program 17 and sex-specific distributions of lipid concentrations in the Lipid Research Clinics 18 and grouped participants on the basis of their baseline lipid concentrations as follows: (1) HDL-C (mg/dL): for men; Ͻ40, 40 to 54, Ն55 (referent group); for women; Ͻ50, 50 to 64, Ն65 (referent group); and (2) non-HDL-C (mg/dL): Ͻ160 (referent group), 160 to 189, Ն190.
We first ascertained HF event proportions and age-and sexadjusted HF event rates in each lipid category. We then incorporated lipid categories as predictor variables in the aforementioned models and related the categories to HF incidence.
Because lipid concentrations and values of other covariates change over time and these changes may influence the relations of lipids to HF incidence, we repeated Cox proportional hazards regression updating lipid concentrations and the complete covariate profile approximately every 8 years after the initial baseline (every fourth examination for the original cohort and approximately every other examination for the offspring cohort) for each participant. For analyses of lipid categories, participants were regrouped on the basis of the lipid levels at the beginning of the relevant 8-year period. If a participant experienced a MI, angina pectoris, coronary insufficiency, or HF event before a given 8-year interval, the participant was considered as having a prevalent event and was excluded for that and all subsequent 8-year intervals. If a participant had valve disease or was receiving lipid-lowering therapy or had missing lipid information at the beginning of a given 8-year period, we excluded that person for that analysis interval. We also performed tests for sex interaction to determine whether there was need for sex-specific analyses.
Nonoptimal lipid concentrations are widely prevalent in the population. 19 Therefore, we sought to evaluate the population burden of HF secondary to dyslipidemia by calculating category-specific population attributable risk (PAR) as a function of the proportion of cases (Pd) of HF occurring in each category of HDL-C and non-HDL-C and the relative risk (RR) (the hazard ratio from the model adjusting for clinical covariates). The formula we used (expressing PAR as a percentage) is as follows: PARϭPd [(RRϪ1)/RR]ϫ100.
Hazard ratios are expressed per SD increment in a lipid value (for analyses in which lipids were used as continuous variables) or comparing the nonoptimal lipid concentrations with the referent category. A P value threshold of 0.05 was used to determine statistical significance. All statistical analyses were performed with the use of SAS software version 8.0 (SAS Institute, Cary, NC).
Results
The baseline characteristics of the study sample are detailed in Table 1 . Overall, 58% of participants were alive at the end of the follow-up period and were censored at that point. Causes of death in the others were as follows: CHD (6%), other cardiovascular causes (6%), cancer (12%), other noncardiovascular or noncancer deaths (14%), and unknown (4%). Over a mean follow-up of 26 years (maximum, 37 years), 680 participants (10%; 335 women, 345 men) developed a first HF event. For those participants who developed HF, mean time to event was 21 years (median, 22 years; range, 0.15 to 35 years). Of participants who developed HF, 41% had a preceding MI. Among participants who developed HF, the proportion with interim MI rose from 33% to 48% across categories of increasing non-HDL-C. The proportion of HF cases with interim MI decreased from 48% to 28% across categories of increasing HDL-C. Tests for sex interactions were negative; therefore, only sex-pooled results are presented here. HF event rates increased across categories of non-HDL-C and decreased across categories of HDL-C in both analyses modeling only baseline lipid concentrations and those incorporating periodically updated lipid concentrations. Table 2 presents analyses modeling baseline lipid concentrations and periodically updated lipid concentrations as continuous variables. Table 3 (baseline) and Table 4 (periodically updated) present analyses modeling lipid categories. Participants in the lower categories of HDL-C and higher categories of non-HDL-C received ␤-blockers, diuretics, and angiotensin-converting enzyme inhibitors, drugs that may favorably alter the risk of HF, in higher proportions than participants in the referent groups (Table II in 
Relations of HDL-C to HF Incidence
In analyses modeling HDL-C as a continuous variable, we observed an 18% lower risk for HF with each SD increase in baseline HDL-C levels ( Table 2 ). When HDL-C concentrations were updated at each examination, the decrement in HF risk was 23% for each SD increase of HDL-C ( Table 2 ). Even after adjustment for interim MI, both baseline and periodically up-dated HDL-C concentrations were significantly related to HF incidence (11% and 16% lower HF risk per SD increase in baseline and updated HDL-C levels, respectively; Table 2 ).
In models incorporating HDL-C categories (Table 3) , participants in intermediate and high baseline HDL-C categories experienced a 23% and 40% lower risk of HF, respectively, compared with the low HDL-C group. When HDL-C values were updated every 8 years, participants in the intermediate and high HDL-C categories experienced a 21% and 43% lower HF risk, respectively, compared with the low HDL-C category ( Table 4 ). In analyses adjusted for interim MI, there was a modest attenuation of the hazard ratios, but the inverse relation between HDL-C levels and HF risk persisted (Tables 3 and 4 ). Kaplan-Meier curves for survival free of HF in each HDL-C category are presented in Figure 1 . (43) HDL-C, mg/dL 52 (16) Non-HDL-C, mg/dL 156 (45) Values are mean (SD) or percentage. Interim MI indicates MI that occurred between baseline examination and diagnosis of HF. Analyses of single baseline measurements were based on a mean of 26 years (maximum, 37 years) of follow-up.
Multivariable models were adjusted for the following covariates: age, sex, body mass index, systolic blood pressure, hypertension treatment, diabetes mellitus, and smoking. HR indicates hazard ratio per SD change in lipid value; CI, confidence interval; and interim MI, MI occurring between baseline examination and diagnosis of HF. 
Relations of Non-HDL-C to HF Incidence
Participants with elevated baseline and periodically updated ( Table 2 ) non-HDL-C concentrations were at a 19% and 23% higher risk for HF, respectively. These relations remained robust even after adjustment for interim MI; we observed an 11% increment in HF risk for each SD increment in non-HDL-C (Table 2) . When modeled as a categorical variable, participants in the highest category of non-HDL-C were at increased risk compared with participants in the lowest non-HDL-C group. Adjustment for MI modestly attenuated the effect size.
Population Attributable Risk
The hazards associated with lipids and other HF risk factors and the corresponding PARs are presented in Figure 2 and Table III in 
Discussion
Principal Findings
In our large community-based sample of adults free of prevalent CHD, elevated non-HDL-C and decreased HDL-C were associated with increased risk of HF. The relations of lipid concentrations to HF incidence were continuous and graded in models adjusting for established HF risk factors and persisted after adjustment for interim MI. A novel finding of our study is the inverse association between HDL-C concentrations and HF risk. HDL-C was especially robust as a predictor, whether modeled as a continuous or categorical variable and when assessed as a single baseline measurement or a periodically updated measure, and 15% of all cases of HF were attributable to low HDL-C concentrations (Ͻ40 mg/dL in men and Ͻ50 mg/dL in women).
Dyslipidemia is a risk factor for atherosclerosis, and predisposition to MI is one mechanism by which lipids promote the occurrence of HF. In our investigation, after excluding baseline CHD and accounting for interim MI, we observed an enduring relation between lipid concentrations and HF incidence, suggesting an influence of lipids on HF risk that is not mediated by MI. Although results from observational studies cannot establish causation, the strength, direction, and continuous nature of the association and the temporal sequence are consistent with a causal relation. However, it is possible that the relations of lipid level abnormalities to HF risk that are unexplained by clinically diagnosed MI are driven by unrecognized infarction. Indeed, it has been estimated that a quarter to a third of all MIs are clinically undetected. 20, 21 Thus, the residual HF risk we observed after adjustment for clinical MI may be due to undetected events.
Lipids and HF: Comparison With the Published Literature
Previous observational studies have addressed associations of lipid measures with incidence of HF. Kannel et al 5 reported that an elevated total cholesterol/HDL-C ratio is associated with increased HF risk. Another report from the Framingham Heart Study noted an association, albeit of modest magnitude, between total cholesterol and HF risk. 22 Elevated triglycerides have been implicated in HF incidence in the elderly. 4 One case-control study reported independent associations between decreased HDL-C and elevated triglycerides and dilated cardiomyopathy. 23 Ingelsson et al 24 identified decreased HDL-C and an elevated apolipoprotein B/A-1 ratio (the ratio of the main lipoproteins in low-density lipoprotein cholesterol and HDL-C, respectively) as independent predictors of HF risk in a prospective community-based study. Investigators from the Physicians' Health Study identified egg consumption (a rich source of cholesterol) as a risk factor for HF. 25 Similarly, increased intake of saturated fat was also implicated as a HF risk factor in a report from the Atherosclerosis Risk in Communities study. 26 Another prospective study from Uppsala identified metabolic syndrome (typically associated with elevated triglycerides and low HDL-C) as a HF risk factor. 27 Prior investigations, however, were limited by lack of systematic exclusion of baseline CHD and did not consistently adjust for a panel of clinical covariates including interim MI. Furthermore, previous studies did not assess the full range of lipid level alterations.
Lipids and HF: Possible Mechanisms Underlying the Observed Association
Although some have argued that dyslipidemia influences risk of MI but not of HF, 28 a hypothesis that is supported by our study is that lipid abnormalities exert effects on the myocardium independent of MI. Several lines of evidence implicate lipid derangements in the development of abnormal cardiac structure and function. Observations in humans demonstrate that elevated total cholesterol is related to increased blood pressure, 29 increased arterial stiffness, 30 decreased vascular compliance, 29 and increased left ventricular mass and wall thickness. 29, 31 Experimental evidence from animals fed a high-cholesterol diet shows that diet-induced hypercholesterolemia leads to decreased systolic and diastolic function, 32 increased left ventricular enddiastolic volume and pressure, 33 and decreased myocardial perfusion responsiveness to stress. 34 Decreased HDL-C concentrations are associated with increased left ventricular mass, 35 decreased diastolic function, 36 and a lower ejection fraction in people with both normal and stenosed coronary arteries. 37 In addition, retrospective analyses from some clinical trials demonstrated a decrease in the incidence of HF in people with dyslipidemia treated with lipid-modifying therapy. 3 Clinical trials have also demonstrated improved outcomes after treatment with statins in individuals with HF who have dyslipidemia but no discernible CHD. 38 The inverse association between HDL-C concentrations and HF risk may be mediated by the cardiovascular protective effects of the HDL particle. Apart from amelioration of atherosclerosis by promoting cholesterol efflux from macrophages (and thereby decreasing MI risk and risk of post-MI HF), HDL and its constituent proteins have pleiotropic biological effects. 39 Inflammation has been implicated previously in HF development, 40 and HDL has anti-inflammatory properties 41 and can therefore exert a protective effect. HDL also inhibits expression of cell surface adhesion molecules that promote monocyte infiltration into the endothelium, 42 further reducing the inflammatory processes that are precursors to clinical HF. Elevated HDL concentrations improve endothelial function 43 and reduce low-density lipoprotein oxidation, 44 thereby protecting against vascular remodeling and myocardial ischemia. HDL also improves endothelial repair mediated by progenitor cells, 45 thus decreasing the risk of cardiac and vascular remodeling. These mechanisms may explain the "protective" effect of HDL-C.
Of note are 2 recent clinical trials that evaluated the efficacy of rosuvastatin in reducing the risk of cardiovascular death, nonfatal cardiovascular events, and HF hospitalization in patients with established class II, III, and IV HF. Neither the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial 46 nor the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza cardiac (GISSI-HF) trial 47 found a survival benefit in HF patients from treatment with this agent. HF is an end-stage event and is a manifestation of a lifetime of risk factor exposure, myocardial injury, and fibrosis. Thus, it is possible that although abnormal lipid concentrations influence the risk for new-onset HF, modifying lipid levels in patients with established HF may not improve survival because the myocardial damage at that stage of disease may not be remediable to lipid-lowering therapy.
Strengths and Limitations
A strength of this study is the large sample size and number of events, judicious exclusions at baseline to minimize confounding by prevalent CHD, careful surveillance for and standardized definition of HF events, comprehensive analyses of major lipid subfractions without and with adjustment for interim MI on follow-up, and the use of models to assess both intermediate and long-term effects of altered lipid concentrations.
Nevertheless, several limitations of our study should be recognized. Although we were careful to exclude prevalent CHD, the results may be confounded by undetected disease present at baseline or unrecognized events occurring during follow-up. Triglycerides measurements were not consistently available at all examination cycles and in all participants, and therefore we were unable to evaluate the relations of triglycerides (or calculate low-density lipoprotein cholesterol concentrations) to HF risk. Aggressive treatment of hypertension, diabetes mellitus, and dyslipidemia and concurrent lifestyle changes after MI may modify the magnitude of risk associated with these factors, a confounding effect that is not fully accounted for by our time-dependent analyses. It is possible that differences across lipid categories in the use of diuretics, ␤-blockers, and angiotensin-converting enzyme inhibitors, drugs that may prevent HF, influenced our results. Because more participants in the high-risk lipid groups received these agents compared with the referent groups ( Table II in the online-only Data Supplement), this disproportion in potentially beneficial treatment across groups may have biased our results toward the null. We lacked information on ejection fraction and were thus unable to ascertain whether lipid concentrations were related to HF with reduced ejection fraction, HF with normal ejection fraction, or both. Finally, our study sample was composed of individuals of European descent, and therefore our results may not be generalizable to other ethnic groups.
Conclusions
On the basis of a comprehensive evaluation of lipid concentrations derived from prospective observation of a healthy, free-living sample, we demonstrate that elevated levels of non-HDL-C and decreased levels of HDL-C are associated with increased risk of HF. It is noteworthy that 15% of HF cases were attributable to low HDL-C concentrations. The HF risk associated with dyslipidemia appears to be partly independent of the influence of lipids on risk of MI. These findings lend mechanistic support to previous observations of benefit from lipid therapy in reducing HF incidence. Given the high prevalence of dyslipidemia in the community, 19 our report highlights the possibility of reducing HF burden by targeting abnormal lipid concentrations for treatment.
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